Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of loracarbef in the treatment of pneumonia.
Am J Med. 1992 Jun 22; 92(6A):65S-69S.AJ

Abstract

The treatment of bacterial pneumonia requires an agent with activity against a wide range of bacterial pathogens, including pathogens that produce beta-lactamase. Loracarbef, a member of the carbacephem class of antibiotics, was tested in a series of clinical trials for its efficacy and safety in the treatment of lobar and bronchial bacterial pneumonia. Successful clinical responses were achieved in 97.6% of the evaluable patients receiving 400 mg twice daily of loracarbef. This compared favorably with the respective response rates of 92.3% for patients receiving 500 mg three times a day of amoxicillin/clavulanate and 95.0% for patients receiving 500 mg three times a day of amoxicillin for the same illnesses. Proven or presumed elimination of the pretherapy pathogen was found in 89% of the patients receiving loracarbef, 92.3% of the amoxicillin/clavulanate-treated patients, and 70.0% of those receiving amoxicillin. Loracarbef was also well tolerated, although nausea and vomiting were associated with the use of all three agents. Nevertheless, treatment with loracarbef resulted in the lowest rate of discontinuation of therapy due to drug-related adverse events. Thus, these clinical trials support the conclusion that loracarbef is a safe and effective treatment for bacterial pneumonia.

Authors+Show Affiliations

Lilly Research Laboratories, Wishard Memorial Hospital, Indianapolis, Indiana 46202.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

1621747

Citation

Hyslop, D L.. "Efficacy and Safety of Loracarbef in the Treatment of Pneumonia." The American Journal of Medicine, vol. 92, no. 6A, 1992, 65S-69S.
Hyslop DL. Efficacy and safety of loracarbef in the treatment of pneumonia. Am J Med. 1992;92(6A):65S-69S.
Hyslop, D. L. (1992). Efficacy and safety of loracarbef in the treatment of pneumonia. The American Journal of Medicine, 92(6A), 65S-69S.
Hyslop DL. Efficacy and Safety of Loracarbef in the Treatment of Pneumonia. Am J Med. 1992 Jun 22;92(6A):65S-69S. PubMed PMID: 1621747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of loracarbef in the treatment of pneumonia. A1 - Hyslop,D L, PY - 1992/6/22/pubmed PY - 1992/6/22/medline PY - 1992/6/22/entrez SP - 65S EP - 69S JF - The American journal of medicine JO - Am J Med VL - 92 IS - 6A N2 - The treatment of bacterial pneumonia requires an agent with activity against a wide range of bacterial pathogens, including pathogens that produce beta-lactamase. Loracarbef, a member of the carbacephem class of antibiotics, was tested in a series of clinical trials for its efficacy and safety in the treatment of lobar and bronchial bacterial pneumonia. Successful clinical responses were achieved in 97.6% of the evaluable patients receiving 400 mg twice daily of loracarbef. This compared favorably with the respective response rates of 92.3% for patients receiving 500 mg three times a day of amoxicillin/clavulanate and 95.0% for patients receiving 500 mg three times a day of amoxicillin for the same illnesses. Proven or presumed elimination of the pretherapy pathogen was found in 89% of the patients receiving loracarbef, 92.3% of the amoxicillin/clavulanate-treated patients, and 70.0% of those receiving amoxicillin. Loracarbef was also well tolerated, although nausea and vomiting were associated with the use of all three agents. Nevertheless, treatment with loracarbef resulted in the lowest rate of discontinuation of therapy due to drug-related adverse events. Thus, these clinical trials support the conclusion that loracarbef is a safe and effective treatment for bacterial pneumonia. SN - 0002-9343 UR - https://www.unboundmedicine.com/medline/citation/1621747/Efficacy_and_safety_of_loracarbef_in_the_treatment_of_pneumonia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9343(92)90610-N DB - PRIME DP - Unbound Medicine ER -